Endocr Connect 2023;12:e220504.ArticlePubMedPMC 4
On average, individuals taking semaglutide can expect to lose about 6% of their starting body weight within the first three months of treatment
If the FDA will require outcomes trials for future approvals in obesity, this will add considerable time and cost to drug development
As of December 2024, the FDA approved tirzepatide for treatment of moderate-to-severe obstructive sleep apnea (OSA) in patients with obesity based on the results of two trials
In case of any issues, contact us Email ID: [email protected] Phone Number: 0124-4166666 Address: 5th Floor Tower - B of the Presidency Building, 46/4 Mehrauli Gurgaon Road, Sector 14, Gurugram, Haryana-122001, India 1777 2369 25% off 60 vegicaps Save more with additional offers Flat Rs.150 on a Min Transaction of Rs.1000
Fractionated superficial radiotherapy, a specific type of radiation therapy, has recurrence rates of between 5% to 14%